


# mRNA Vaccine Adverse Events – Epidemiologic Studies

**Brian Hooker, PhD**


Chief Scientific Officer  
Children's Health Defense




## Odds Ratios for Bell's Palsy Following mRNA COVID-19 Vaccination




## Odds Ratios for Bell's Palsy Following the BNT162b2 and CoronaVac COVID-19 Vaccines




## Increased Risk of Bell's Palsy After First Dose of Pfizer BNT162b2 COVID-19 Vaccine




# Increased Odds of Hospitalization with Bell's Palsy After Pfizer BNT162b2 COVID-19 Vaccination




## Risk of Cardiac Adverse Events Following mRNA COVID-19 Vaccination



## Increased Risk of Myocarditis in Adolescents After the BNT162b2 COVID-19 Vaccine




# Increased Risk for Myocarditis in Males 16 to 24 Years Following the Second BNT162b2 and mRNA-1273 COVID-19 Vaccines







### Risk of Myocarditis in Men After the First, Second, or Third mRNA-1273 COVID-19 Vaccine




## Increased Risk of Myocarditis Within 7 Days of mRNA COVID-19 Vaccines




## Increased Odds of Carditis After the Pfizer BNT162b2 COVID-19 Vaccine




# Increased Risk of Myocarditis After the Pfizer BNT162b2 COVID-19 Vaccine




### Increased Risk of Myocarditis/Pericarditis in Males Aged 12 to 39 Within 7 Days After the mRNA-1273 COVID-19 Vaccine



## Increased Risk of Myocarditis/Pericarditis in Persons Aged 18 to 39 Within 7 Days After mRNA COVID-19 Vaccines




# Increased Risk of Shingles After the BNT162b2 COVID-19 Vaccine



Shingles


- 0-13 days after first dose
- 14-27 days after first dose
- 0-13 days after second dose
- baseline period

## Increased Risk of Sudden Sensorineural Hearing Loss Following the BNT162b2 COVID-19 Vaccine






## Increased Risk of Adverse Events From COVID-19 Vaccines Versus Influenza Vaccines



## Increased Risk of Various Adverse Events among Elderly Persons Aged 65 Years and Older Following Pfizer BNT162b2 COVID-19 Vaccination



## Risk Ratios for Serious Adverse Events Following mRNA COVID-19 Vaccination

